Skip to main content
. 2021 Dec 17;14:2115–2134. doi: 10.2147/PRBM.S292958

Figure 1.

Figure 1

Reward Deficiency Syndrome SolutionTM for identification of risk alleles with the Genetic Addiction Risk Severity (GARS). The figure describes the Reward Deficiency Syndrome Solution SystemTM that proposes using the Genetic Addiction Risk Severity (GARS) to identify and stratify risk alleles for targeting by individualized nutrigenomic preparations. Our approach called “Precision Behavioral Management” consists of; 1) Early pre-disposition assessment and determination (even in children) with the Genetic Addiction Risk Severity (GARS), a 10 candidate polymorphic gene panel shown to predict ASI-alcohol and drug severity; 2) validated RDS questionnaire; 3) Utilization of the Comprehensive Analysis of Reported Drugs (CARD™) during actual treatment to determine compliance with prescribed medications and abstinence from non-prescribed and illicit drugs of abuse, and importantly; 4) Utilization of a “Pro-Dopamine Regulator (KB220)” (via IV and oral [KB220Z] delivery systems) to prevent relapse by induction of dopamine homeostasis, and; 5) Utilization of targeted DNA polymorphic reward genes to direct mRNA genetic expression profiling during the treatment process.